IDBS, a provider of research data management and analytics solutions to R&D organizations,announced that its next generation Electronic Laboratory Notebook (ELN), E-WorkBook, has received certification from the SAFE-BioPharma Association, the pharmaceutical and healthcare industry’s non-profit association for digital identity and signature standards.
“IDBS was one of the first vendors to join SAFE-BioPharma Association and was the first ELN provider to join. We are pleased that E-WorkBook is certified as fully compliant with the standard,” said Mollie Shields-Uehling, president and CEO of SAFE-BioPharma. Certification provides SAFE-BioPharma members with the assurance that the IDBS E-WorkBook meets the digital signature standard that the industry requires.
E-WorkBook is an enterprise scale ELN, which is now used across the whole cycle of drug research and development in areas such as biomarker discovery, medicinal and synthetic chemistry, DMPK, pharmacology, bioanalysis, formulations, toxicology and immunology. It captures, computes and stores research data in a secure and traceable environment, and now offers a superior level of digital signature integration compared to any other ELN. SAFE-BioPharma certification confirms that IDBS’ customers can integrate their SAFE-BioPharma digital signature infrastructures to E-WorkBook using plug-and-play, without the need for any customization.
E-WorkBook enables class-leading protection and exploitation of corporate Intellectual Property (IP) and ensures that all data can be searched, mined and and leveraged with confidence and knowledge of its validity and security. Furthermore, regulatory compliant SAFE-BioPharma digital identities can now be applied in E-WorkBook 8.2 using ‘plug and play’ for additional support of Good Laboratory and Manufacturing Practice (GLP and GMP) records management.
“Pharmaceutical and Biotech companies need to have an ELN that can easily be integrated with any digital signature system. Simply having a legacy ELN to store a paper trail equivalent is not enough to protect their IP,” said Neil Kipling, founder and CEO of IDBS. “E-WorkBook’s new ‘plug and play’ capability with any SAFE-BioPharma compliant digital signature infrastructure raises the bar for other ELNs to meet. Our large and growing customer community around the world can be assured that they have robust and defensible records of their research and that of their collaborators, and that IP is protected and defended to a superior standard.”
Release Date: December 7, 2009
Source: IDBS